Epidemiology of Narcolepsy Type 1 and Type 2 in Spain (NCT07299097) | Clinical Trial Compass
RecruitingNot Applicable
Epidemiology of Narcolepsy Type 1 and Type 2 in Spain
Spain100 participantsStarted 2025-12-02
Plain-language summary
The main purpose of this study is to find out how many people in Spain have been diagnosed with narcolepsy type 1 and type 2, and how many new participants are diagnosed each year. Narcolepsy is a rare sleep disorder that causes excessive daytime sleepiness. The researchers will look at medical records from hospitals across Spain to count participants with these conditions and understand patterns in diagnosis over time.
Who can participate
Age range
0 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Participants with NT1 or NT2 following International Classification of Sleep Disorders, 3rd Edition (ICSD-3) or ICSD-3 text revision (ICSD-3-TR) criteria who are alive at any point during 2023 or 2024.
. Any age, ethnicity and nationality.
. Treated / under follow-up in the study site and residing in the hospitals' reference areas. Consideration will be given if participants have changed their address or reached adulthood.
Exclusion criteria
. Confirmation to have a diagnosis of NT1 or NT2 by a specialist.
. Participants greater than equal to (≥) 18 years or parents of narcolepsy participants under 18 years of age.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Core Group: Prevalence of Participants With NT1 and NT2 per 100,000 Population
Timeframe: Up to 1 year
2
Core Group: Prevalence of Adult Participants With NT1 and NT2 per 100,000 Adult Population
Timeframe: Up to 1 year
3
Core Group: Prevalence of Paediatric/Adolescent Participants With NT1 and NT2 per 100,000 Paediatric/Adolescent Population
Timeframe: Up to 1 year
4
Core Group: Prevalence of Male Participants With NT1 and NT2 per 100,000 Male Population
Timeframe: Up to 1 year
5
Core Group: Prevalence of Female Participants With NT1 and NT2 per 100,000 Females Population
Timeframe: Up to 1 year
6
Core Group: Incidence of NT1 and NT2 per 100,000 Population
Timeframe: Up to 2 years
7
Core Group: Incidence of NT1 and NT2 per 100,000 Adult Population